Cogent Biosciences (COGT) Operating Leases (2019 - 2026)

Cogent Biosciences (COGT) has reported Operating Leases for 8 consecutive years, with $14.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 8.93% year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at $14.1 million (down 8.93% YoY), while the FY2025 annual figure was $14.4 million, down 9.73% from the prior year.
• Operating Leases fell to $14.1 million in Q1 2026 per COGT's latest filing, from $14.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $19.0 million in Q2 2022 and bottomed at $1.1 million in Q1 2022.
• Historically, Operating Leases has averaged $15.8 million across 5 years, with a median of $16.7 million in 2024.
• On a YoY basis, Operating Leases climbed as much as 2093.26% in 2022 and fell as far as 56.74% in 2022.
• Cogent Biosciences' Operating Leases stood at $18.2 million in 2022, then slipped by 4.16% to $17.5 million in 2023, then retreated by 8.96% to $15.9 million in 2024, then fell by 9.73% to $14.4 million in 2025, then retreated by 1.8% to $14.1 million in 2026.
• Business Quant data shows COGT's Operating Leases at $14.1 million in Q1 2026, $14.4 million in Q4 2025, and $14.6 million in Q3 2025.